Net debt/EBITDA was 1.7 times in fiscal 2023, but we expect this ratio to increase temporarily above 3 times with the acquisition of 1E. Leverage should decline again in the next few years given the ...
Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果